Evidence map›Paper›PMID 41373733›Full record

ArticleInternational journal of molecular sciences2025

Construction of Metastasis Prediction Models and Screening of Anti-Metastatic Drugs Based on Pan-Cancer Single-Cell EMT Features.

Yingqi Xu, Yawen Luo, Maohao Li, Na Lv, Yuanyuan Deng, Ning Li, Shichao Wan, Xing Gao, Xia Li, Congxue Hu

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yingqi XuCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
Yawen LuoCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.ORCID 0009-0003-9031-1864
Maohao LiCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
Na LvCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
Yuanyuan DengCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
Ning LiCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
Shichao WanCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
Xing GaoCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.ORCID 0009-0006-8390-1403
Xia LiCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
Congxue HuCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.

Funding

China Postdoctoral Science Foundation 2024M760709Heilongjiang Postdoctoral Fund LBH-Z24210Heilongjiang Provincial Natural Science Foundation LH2023C061National Natural Science Foundation of China 32570792National Natural Science Foundation of China 62502128National Science and Technology Major Program 2024ZD0530500the Key Research and Development Program of Heilongjiang Province 2024ZX12C27
6 · The paper itself

Abstract

Tumor metastasis is the leading cause of death in cancer patients, with epithelial-mesenchymal transition (EMT) playing a key role. To systematically elucidate the cellular mechanisms and molecular networks through which EMT drives metastasis across cancers, this study integrated transcriptomic data from over 1.2 million single cells across 265 samples representing 12 primary epithelial cancers, constructing a comprehensive pan-cancer single-cell atlas covering diverse stages and metastatic states. By analyzing the metastatic features and interaction networks of malignant epithelial cells and cancer-associated fibroblasts (CAFs), we identified cancer-specific metastasis-related gene sets. Based on these genes, multiple machine learning algorithms were applied to build cancer-specific and cross-cancer metastasis prediction models, leading to the development of the metastasis prediction score (MPS) and global metastasis prediction score (GMPS). Both scores showed excellent predictive performance in independent test and external validation cohorts. MPS exhibited higher cancer specificity, whereas GMPS showed stronger cross-cancer generalization. Moreover, elevated MPS and GMPS reflected immunosuppressive tumor microenvironment features and were significantly associated with poor prognosis across multiple cancer types. Finally, through a drug repositioning framework, we identified several potential anti-metastatic compounds targeting the metastasis network, among which Fostamatinib demonstrated broad-spectrum therapeutic potential against metastasis in multiple cancers.

Indexed as

Antineoplastic AgentsEpithelial-Mesenchymal TransitionNeoplasmsCancer-Associated FibroblastsGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMachine LearningNeoplasm MetastasisPrognosisSingle-Cell AnalysisTumor MicroenvironmentAntineoplastic Agentsdrug screeningepithelial–mesenchymal transitionmetastasis prediction modelsingle-cell RNA sequencing

Identifiers

PMID41373733
PMCPMC12692492

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.